Early (1-year) Discontinuation of Different Anti-osteoporosis Medications Compared: A Population-Based Cohort Study
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 605520488 | ||
| 003 | CHVBK | ||
| 005 | 20210128100735.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 210128e20151201xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1007/s00223-015-0040-3 |2 doi |
| 035 | |a (NATIONALLICENCE)springer-10.1007/s00223-015-0040-3 | ||
| 245 | 0 | 0 | |a Early (1-year) Discontinuation of Different Anti-osteoporosis Medications Compared: A Population-Based Cohort Study |h [Elektronische Daten] |c [C. Carbonell-Abella, A. Pages-Castella, M. Javaid, X. Nogues, A. Farmer, C. Cooper, A. Diez-Perez, D. Prieto-Alhambra] |
| 520 | 3 | |a Although a number of reports suggest very low persistence with oral bisphosphonates, there is limited data on persistence with other anti-osteoporosis medications. We compare rates of early discontinuation (in the first year) with all available outpatient anti-osteoporosis drugs in Catalonia, Spain. We conducted a population-based retrospective cohort study using data from the SIDIAP database. SIDIAP contains computerized primary care records and pharmacy dispensing data for >80% of the population of Catalonia (>5 million people). All SIDIAP participants starting an anti-osteoporosis drug between 1/1/2007 and 30/06/2011 (with 2years wash-out) were included. We modelled persistence as the time between first prescription and therapy discontinuation (refill gap of at least 6months) using Fine and Gray survival models with competing risk for death. We identified 127,722 patients who started any anti-osteoporosis drug in the study period. The most commonly prescribed drug was weekly alendronate (N=55,399). 1-Year persistence ranges from 40% with monthly risedronate to 7.7% with daily risedronate, and discontinuation was very common [from 49.5% (monthly risedronate) to 84.4% (daily risedronate)] as was also switching in the first year of therapy [from 2.8% (weekly alendronate) to 10% (daily alendronate)]. Multivariable-adjusted models showed that only monthly risedronate had better one-year persistence than weekly alendronate and teriparatide equivalent, whilst all other therapies had worse persistence. Early discontinuation with available anti-osteoporosis oral drugs is very common. Monthly risedronate, weekly alendronate, and daily teriparatide are the drugs with the best persistence, whilst daily oral drugs have 40-60% higher first-year discontinuation rates compared to weekly alendronate. | |
| 540 | |a Springer Science+Business Media New York, 2015 | ||
| 690 | 7 | |a Electronic health records |2 nationallicence | |
| 690 | 7 | |a Epidemiology |2 nationallicence | |
| 690 | 7 | |a Medication adherence |2 nationallicence | |
| 690 | 7 | |a Osteoporosis |2 nationallicence | |
| 690 | 7 | |a Catalonia |2 nationallicence | |
| 690 | 7 | |a Primary health care |2 nationallicence | |
| 700 | 1 | |a Carbonell-Abella |D C. |u GREMPAL Research Group, IDIAP Jordi Gol, Universitat Autònoma de Barcelona, Barcelona, Spain |4 aut | |
| 700 | 1 | |a Pages-Castella |D A. |u GREMPAL Research Group, IDIAP Jordi Gol, Universitat Autònoma de Barcelona, Barcelona, Spain |4 aut | |
| 700 | 1 | |a Javaid |D M. |u Oxford NIHR BRU, NDORMS, University of Oxford, Oxford, UK |4 aut | |
| 700 | 1 | |a Nogues |D X. |u Musculoskeletal Research Unit, FIMIM, Parc Salut Mar, and RETICEF, Barcelona, Spain |4 aut | |
| 700 | 1 | |a Farmer |D A. |u Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK |4 aut | |
| 700 | 1 | |a Cooper |D C. |u Oxford NIHR BRU, NDORMS, University of Oxford, Oxford, UK |4 aut | |
| 700 | 1 | |a Diez-Perez |D A. |u Musculoskeletal Research Unit, FIMIM, Parc Salut Mar, and RETICEF, Barcelona, Spain |4 aut | |
| 700 | 1 | |a Prieto-Alhambra |D D. |u GREMPAL Research Group, IDIAP Jordi Gol, Universitat Autònoma de Barcelona, Barcelona, Spain |4 aut | |
| 773 | 0 | |t Calcified Tissue International |d Springer US; http://www.springer-ny.com |g 97/6(2015-12-01), 535-541 |x 0171-967X |q 97:6<535 |1 2015 |2 97 |o 223 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s00223-015-0040-3 |q text/html |z Onlinezugriff via DOI |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 900 | 7 | |a Metadata rights reserved |b Springer special CC-BY-NC licence |2 nationallicence | |
| 908 | |D 1 |a research-article |2 jats | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-springer | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1007/s00223-015-0040-3 |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Carbonell-Abella |D C. |u GREMPAL Research Group, IDIAP Jordi Gol, Universitat Autònoma de Barcelona, Barcelona, Spain |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Pages-Castella |D A. |u GREMPAL Research Group, IDIAP Jordi Gol, Universitat Autònoma de Barcelona, Barcelona, Spain |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Javaid |D M. |u Oxford NIHR BRU, NDORMS, University of Oxford, Oxford, UK |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Nogues |D X. |u Musculoskeletal Research Unit, FIMIM, Parc Salut Mar, and RETICEF, Barcelona, Spain |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Farmer |D A. |u Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Cooper |D C. |u Oxford NIHR BRU, NDORMS, University of Oxford, Oxford, UK |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Diez-Perez |D A. |u Musculoskeletal Research Unit, FIMIM, Parc Salut Mar, and RETICEF, Barcelona, Spain |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Prieto-Alhambra |D D. |u GREMPAL Research Group, IDIAP Jordi Gol, Universitat Autònoma de Barcelona, Barcelona, Spain |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t Calcified Tissue International |d Springer US; http://www.springer-ny.com |g 97/6(2015-12-01), 535-541 |x 0171-967X |q 97:6<535 |1 2015 |2 97 |o 223 | ||